ANT-GROUP
19.4.2022 15:33:12 CEST | Business Wire | Press release
Ant Group today announced it has achieved carbon neutrality in its own operations (Scopes 1 & 2), according to 2021 emission figures certified by the China Environmental United Certification Center (CEC). This marks the Company’s first major step towards fulfilling the commitments it made in March 2021 to achieve net zero in carbon emissions by 2030 , including providing periodic updates on its progress towards achieving this important goal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005649/en/
According to CEC certified figures, in 2021, Ant Group reduced a total of 37,909.87 tons of CO2 e, equivalent to taking 15,000 cars off the road each year, assuming each car is driven 12,000 kilometers per year at 0.203 kilogram of CO2 e per kilometer.
To validate its results, the CEC used Carbon Matrix , AntChain’s software-as-a-service (SaaS) product that helps businesses and institutions track and certify corporate carbon emissions on blockchain. The CEC was an official service provider to the 2022 Winter Olympics, measuring the Olympic Committee’s carbon reduction effectiveness.
In 2021, Ant Group achieved carbon neutrality in its own operations (Scopes 1 & 2) through a combination of reductions, substitutions and offsets:
- Reduction: reduced 1,668.60 tons of CO2 e by improving its energy savings and efficiency practices.
- Substitution: avoided 21,883.63 tons of CO2 e through the use of renewable energy.
- Offset: offset 23,159.54 tons of CO2 e through the purchase of China Certified Emission Reductions (CCERs).
“This is a major milestone since we announced our carbon neutrality goal on March 12, 2021,” said Yijie Peng, Vice President of Ant Group. “Leveraging innovative technologies such as blockchain and green computation, we are well underway to achieve an inclusive, green and sustainable future.”
According to Ant Group’s carbon neutrality roadmap, by 2030, the Company will achieve net zero carbon emissions across Scopes 1, 2 and 3. Scope 1 refers to direct emissions as a result of fossil fuel burning from sources Ant Group owns or controls. Scope 2 refers to indirect emissions associated with the purchase of electricity and the use of heating or cooling networks. Scope 3 refers to all other carbon emissions generated along Ant Group’s value chain, such as the use of data centers, business travel and daily commute programs provided by the Company.
In 2021, Ant Group reduced a total of 36,241.27 tons of CO2 e in Scope 3, of which the adoption of green computing technologies contributed to 29,591.48 tons – or about 82% of all the Scope 3 reduction.
Data centers, which are at the core of today’s digital economy, consume a large amount of electricity and generate considerable carbon emissions. Following the adoption of green computing technologies in 2019 – such as online-offline hybrid deployment, cloud-native time-shared scheduling, AI-based auto scaling and OceanBase enterprise-level distributed relational database – Ant Group more than doubled the utilization rates of data servers in three years, while meaningfully reducing its carbon footprint.
Ant Group’s remaining Scope 3 carbon emission reductions came from sourcing environmentally friendly office supplies, and encouraging employees to take public transportation or shared rides – including taxis and carpooling for local business travel.
The CEC’s carbon neutrality certificate for Ant Group (in Chinese language only) is publicly available on the Information Platform for Carbon Neutrality , which is affiliated with the Environmental Development Center of China’s Ministry of Ecology and Environment.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005649/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
